HematologyNews.net

Hematology Xagena

Search results for "Bortezomib"

A phase II study, led by Andre Goy, of the University of Texas M.D. Anderson Cancer Center, Houston, evaluated efficacy and toxicity of Bortezomib ( Velcade ) in 60 patients with relapsed or refractor ...


The FDA ( Food and Drug Administration ) approved a supplemental New Drug Application ( sNDA ) for Velcade ( Bortezomib ). This approval expands the label to include the treatment of patients with m ...


The European Commission has approved the use of Bortezomib ( Velcade ) for Injection as a second-line treatment in patients with multiple myeloma. Bortezomib is indicated as monotherapy for use in ...


A novel strategy devised by Dana-Farber Cancer Institute scientists has proved highly effective in killing drug-resistant multiple myeloma cells in the laboratory. The researchers hope to move rapi ...


Two phase II studies with Bortezomib ( Velcade ) showed very high response rates in front-line multiple myeloma. Overall response rates ranged from 88 to 95 percent with complete and near complete r ...


The results from the phase III APEX study have been published in The New England Journal of Medicine. The study showed Velcade ( Bortezomib ) was superior in survival, time to disease progression, an ...


Researchers at the Johns Hopkins Kimmel Cancer Center have shown that cancer stem cells for multiple myeloma share many properties with normal stem cells and have multiple ways of resisting chemothera ...


Researchers at the Johns Hopkins Kimmel Cancer Center have shown that cancer stem cells for multiple myeloma share many properties with normal stem cells and have multiple ways of resisting chemothe ...


A new three-drug combination has shown in a phase 1/2 clinical trial that it is a highly effective regimen in the treatment of patients newly diagnosed with multiple myeloma.Partial responses or bette ...


Results from a study published in Blood, the Journal of the American Society of Hematology ( ASH ), have demonstrated that inclusion of Carfilzomib ( Kyprolis ), a novel targeted therapy for multiple ...


Bruton's tyrosine kinase ( BTK ) is a mediator of the B-cell-receptor signaling pathway implicated in the pathogenesis of B-cell cancers. In a phase 1 study, Ibrutinib ( Imbruvica ), a BTK inhibitor, ...


Two clinical studies published in the New England Journal of Medicine ( NEJM ) suggest that the novel agent Ibrutinib shows real potential as a safe, effective, targeted treatment for adults with chro ...


The results from PANORAMA-1 ( PANobinostat ORAl in Multiple MyelomA ) trial were presented at ASCO meeting, showing a 37% improvement in progression-free survival ( PFS ) when using the investigationa ...


The Food and Drug Administration ( FDA ) has granted accelerated approval of Kyprolis ( Carfilzomib ) for injection, a proteasome inhibitor, indicated for the treatment of patients with multiple myelo ...


Carfilzomib ( Kyprolis ) is a selective proteasome inhibitor being evaluated for the treatment of relapsed and refractory multiple myeloma. In an open-label, single-arm phase 2 study ( PX-171-003- ...